To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

SUMO pathway inhibition t… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype

Journal article
Authors A. Biederstädt
Z. Hassan
C. Schneeweis
M. Schick
L. Schneider
A. Muckenhuber
Y. Hong
G. Siegers
Lisa M Nilsson
M. Wirth
Z. Dantes
K. Steiger
K. Schunck
S. Langston
H. P. Lenhof
A. Coluccio
F. Orben
J. Slawska
A. Scherger
D. Saur
S. Müller
R. Rad
W. Weichert
Jonas A Nilsson
M. Reichert
G. Schneider
U. Keller
Published in Gut
ISSN 00175749 (ISSN)
Publication year 2020
Published at Sahlgrenska Cancer Center
Language en
Links dx.doi.org/10.1136/gutjnl-2018-3178...
Keywords cancer, pancreatic cancer
Subject categories Cancer and Oncology

Abstract

Objective: Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with an overall 5-year survival rate of 9%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC; however, subtypes of the disease exist, which exhibit extensive resistance to such therapies. Genomic MYC amplifications represent a distinct subset of PDAC with an aggressive tumour biology. It is clear that hyperactivation of MYC generates dependencies that can be exploited therapeutically. The aim of the study was to find and to target MYC-associated dependencies. Design: We analysed human PDAC gene expression datasets. Results were corroborated by the analysis of the small ubiquitin-like modifier (SUMO) pathway in a large PDAC cohort using immunohistochemistry. A SUMO inhibitor was used and characterised using human and murine two-dimensional, organoid and in vivo models of PDAC. Results: We observed that MYC is connected to the SUMOylation machinery in PDAC. Components of the SUMO pathway characterise a PDAC subtype with a dismal prognosis and we provide evidence that hyperactivation of MYC is connected to an increased sensitivity to pharmacological SUMO inhibition. Conclusion: SUMO inhibitor-based therapies should be further developed for an aggressive PDAC subtype. © 2020 American Medical Association. All rights reserved.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?